4(4- (5- nitro- furan- 2- ylmethylene)- 3,5- dioxo- pyrazolidin- 1- yl)- benzoic acid ethyl ester

structure in first source

Also Known As:

4-(4-(5-nitrofuran-2-ylmethylene)-3, 5-dioxopyrazolidin-1-yl)benzoic acid ethyl ester; PYR-41; PYR41 compound

Networked: 10 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester: 10
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - 4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester: 10
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - 4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester: 10
  - Furans: 85
    - 4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester: 10

Experts

1.	Li, Hui-Hua: 2 articles (01/2020 - 10/2018)
2.	Matsuo, Shingo: 2 articles (01/2018 - 01/2018)
3.	Wang, Ping: 2 articles (01/2018 - 01/2018)
4.	Yang, Weng-Lang: 2 articles (01/2018 - 01/2018)
5.	Binari, Richard: 1 article (01/2021)
6.	Hannenhalli, Sridhar: 1 article (01/2021)
7.	Hsieh, Sharon: 1 article (01/2021)
8.	Hu, Yanhui: 1 article (01/2021)
9.	Lord, Christopher J: 1 article (01/2021)
10.	Parkhitko, Andrey A: 1 article (01/2021)

Related Diseases

1.	Dermatitis 10/01/2023 - "Previous studies have shown that PYR-41 has effects on anti-inflammatory, but whether it has therapeutic effects on allergic dermatitis is unclear. "
2.	Neoplasms (Cancer) 10/01/2007 - "Furthermore, PYR-41 inhibits degradation of p53 and activates the transcriptional activity of this tumor suppressor. " 10/01/2007 - "Thus, PYR-41 and related pyrazones provide proof of principle for the capacity to differentially kill transformed cells, suggesting the potential for E1 inhibitors as therapeutics in cancer. " 01/01/2021 - "Finally, we found that drugs targeting the identified RB1 interacting genes/pathways, such as UNC3230, PYR-41, TAK-243, isoginkgetin, madrasin, and celastrol also elicit SL in human cancer cell lines. "
3.	Inflammation (Inflammations) 01/01/2018 - "A mouse model of intestinal I/R injury by clamping the superior mesenteric artery for 45 min was performed to evaluate the effect of PYR-41 treatment on organ injury and inflammation. " 01/01/2018 - "PYR-41 and thalidomide have therapeutic effects on inflammation-associated diseases with side effects such as tumorigenesis. "
4.	Carcinogenesis 01/01/2018 - "PYR-41 and thalidomide have therapeutic effects on inflammation-associated diseases with side effects such as tumorigenesis. "
5.	Atherosclerotic Plaque (Atheroma) 01/01/2020 - "We demonstrated that UBA1 expression was upregulated and mainly derived from macrophages in the atherosclerotic plaques and inactivation of UBA1 by PYR-41 suppressed atherosclerosis development probably through inhibiting macrophage proinflammatory response and oxidative stress. "

Related Drugs and Biologics

1.	Therapeutic Uses
2.	Ubiquitin-Activating Enzymes (Ubiquitin-Activating Enzyme)
3.	Small Interfering RNA (siRNA)
4.	Ubiquitin
5.	Thalidomide (Thalomid)
6.	isoginkgetin
7.	celastrol
8.	TAK-243

Related Therapies and Procedures

1.	Therapeutics